Halozyme Therapeutics Gains 953% Over a Decade, Reports $1.02B 2024 Revenue
An initial $1,000 investment in Halozyme Therapeutics ten years ago would now be worth $10,535.81, a 953.58% gain versus the S&P 500’s 266.59% and gold’s 288.56% returns. Halozyme’s 2024 revenue reached $1.02 billion, up 22% year-over-year, driven by ENHANZE royalties and Xyosted sales.
1. Decade-Long Stock Performance
A $1,000 investment in Halozyme Therapeutics in February 2016 would be worth $10,535.81 as of February 2026, reflecting a 953.58% total return. This performance outpaced the S&P 500’s 266.59% and gold’s 288.56% gains over the same period.
2. ENHANZE Platform and Partnerships
Halozyme’s patented ENHANZE drug delivery technology uses recombinant human hyaluronidase (rHuPH20) to enable subcutaneous formulations. Eight partnered products from Roche, Takeda, J&J, AbbVie and others employ ENHANZE, generating royalties and milestone payments for Halozyme.
3. 2024 Revenue Milestone
Total revenues in 2024 reached $1.02 billion, up 22% year-over-year and marking the first time Halozyme surpassed the $1 billion mark. Growth was driven by incremental Xyosted sales and robust royalties from subcutaneous formulations of J&J’s Darzalex and Roche’s Phesgo.
4. Risks and Future Outlook
Blockbuster drugs like Herceptin and Rituxan face biosimilar competition, posing downside risk to royalty streams. Halozyme’s heavy partner dependence and potential deal terminations remain concerns, while analysts forecast further upside and consensus estimates have been raised.